NCT06700499

A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

A Multicenter, Open Label Phase II Clinical Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 450 (actual)
• Sponsor: Akeso · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open label phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.

Detailed description

This is a multicenter, open label phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate to severe atopic dermatitis. The total duration of the study (including screening period, treatment period and follow-up period) planned for each subject is approximately 25 weeks.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	AK120 300mg Q2W (JAK inhibitor users need to double the initial dose)	AK120 300mg Q2W SC until week 14(JAK inhibitor users need to receive a first dose of 600mg SC)

Timeline

• Start date: 2024-07-08
• Primary completion: 2025-07-31
• Completion: 2025-09-11
• First posted: 2024-11-22
• Last updated: 2026-03-17

Locations

50 sites across 1 country: China